MDM2 and liposarcoma: Dephosphorylation and depletion of MDM2 by the inhibitor of HDAC resulted in increased apoptosis, anti-proliferative effects and cell cycle arrest in liposarcoma cell lines, warranting further evaluation of HDACi as a therapeutic option in MDM2-amplified LPS [114].